Novo Nordisk’s management structure is organised around functional areas: The Executive Management consists of a President and CEO (Lars Rebien Sørensen) a Chief Operating Officer (Kåre Schultz) a Chief Financial Officer (Jesper Brandgaard) a Chief Science Officer (Mads Krogsgaard Thomsen) an Executive Vice President, people, relations and reputation (Lise Kingo) an Executive Vice President, quality, regulatory and business development (Lars Almblom Jørgensen)
A Senior Management Board reports to the Executive Management: Research & Development
Jesper Bøving – Preclinical and CMC Supply
Lars Guldbæk Karlsen – Global Development
Terje Kalland – Biopharmaceuticals Research Unit
Peter Kurtzhals – Diabetes Research Unit Production
Eric Drapé – Diabetes Finished Products
Kim Tosti – Devices and Sourcing
Per Valstorp – Product Supply Operations
Jesper Høiland – International Operations
Roger Moore – Japan & Oceania
Jakob Riis – International Marketing
Martin Soeters – North America Corporate Finance, Legal and IT
Lars Green – Corporate Finance
Lars Fruergaard Jørgensen – IT & Corporate Development
Ole Ramsby – Corporate Legal Quality, regulatory and business development
Mariann Strid Christensen – Quality
Peter Bonne Eriksen – Regulatory Affairs Corporate Stakeholder Relations
Lars Christian Lassen – People and Organisation Novo Nordisk Service companies
Torben Skriver Frandsen – NNIT
Per Jansen – Novo Nordisk Servicepartner
Hans Ole Voigt – NNE Novo Nordisk has production sites in Denmark, France, the US, China and Brazil, and research and development facilities in Denmark, China and the US. Operations are organised into four regions: Europe (regional main office in Zurich)
North America (regional main office in Princeton)
Japan & Oceania (regional main office in Tokyo)
International Operations (regional main office in Zurich). The company has affiliates in 79 countries and markets its products in 179 countries. | 
